drugset / Trial / NCT07637448
EGFR-TKIs Plus PD-1 in EGFR-Mutant Advanced NSCLC
NaSingle-groupOpen-labelTreatment
Summary
This study is an open-label, multicenter, single-arm clinical study.
Timeline
- Start
- 2026-05-21
- Primary completion
- 2029-03-01
- Completion
- 2030-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Almonertinib | Small molecule | — | Oral |
| Subject | Firmonertinib | Small molecule | — | Oral |
| Subject | Osimertinib | Small molecule | — | Oral |
| Subject | Sintilimab | Monoclonal antibody | 200 mg | Intravenous |